This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AboutEfficacy & SafetyDosingDosingInitiating NGENLADosing & StorageDevice DemonstrationOrdering InformationSupport & ResourcesSupport & ResourcesStarter Kits
 
Endocrine HelplineHomecare
 
Formulary PackShared Care Guide TemplateContact UsNICE RecommendationNgenla Patient Case Studies
MaterialsVideosMeetings & Events
My Ngenla PlanMy Ngenla PlanMy Ngenla PlanMy Ngenla Plan Overview 

Prescribing Information for NGENLA▼(somatrogon) can be found here. Prescribing Information for Genotropin (somatropin) can be found here. Adverse event reporting information can be found at the bottom of the page.

Administer NGENLA in 3 Easy Steps

The Ngenla device is designed for patients' ease of use and convenience1, 2,3
Once primed, NGENLA can be administered in 3 steps:

  1. Attach the needle
  2. Adjust the dose 
  3. Inject
Device Demonstration Video (<3 minutes)

Watch National Endocrine Clinical Training Lead Claire Snow demonstrate how to use the Ngenla pen.

Needles with a safety shield have been approved for use with NGENLA in Northen Ireland. Needles with a safety shield do not have an inner needle cap. If in Northen Ireland and using a needle with a safety shield, refer to the manufacturer’s instructions for use when attaching and removing the needle3

For instructions on how to use the NGENLA pen see the PIL for Northern Ireland and 
PIL for Great Britain.

This video demonstrates the 24mg pen. For the 60mg pen the steps are the same - the only difference is during priming, where after two clicks, 1.0mg will be displayed in the window, as opposed to 0.4mg. 

Explore more

Access PIP Codes and key details on how to order NGENLA for your patients.

Ordering Information Loading

Access practical support for initiating patients on NGENLA and learn more about how NGENLA may deliver a treatment experience favoured by patients and caregivers.1

Initiating NGENLA Loading

References:

Maniatis AK, et al. Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study. J Endocr Soc. 2022, 6, 1–10
NGENLA 24mg and 60mg Patient Information Leaflet for Great Britian. Avaliable at www.medicines.org.uk/emc/search?q=ngenlaNGENLA 24mg and 60mg Patient Information Leaflet for Northern Ireland. Avaliable at https://www.emcmedicines.com/en-gb/northernireland/medicines?search=ngenla
PP-NGE-GBR-0718. March 2024.

Find out information about the starter kits available to patients starting treatment with NGENLA.

Starter kits Loading

Download the document to access information supporting fomulary application for NGENLA.

Formulary pack Loading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​